Literature DB >> 21840492

Human papillomavirus and Papanicolaou tests screening interval recommendations in the United States.

Katherine B Roland1, Ashwini Soman, Vicki B Benard, Mona Saraiya.   

Abstract

OBJECTIVE: Guidelines recommend when the human papillomavirus (HPV) and Papanicolaou tests are used together (HPV co-test) for routine cervical cancer screening, screening intervals can be extended to 3 years. We assessed HPV test practices and Papanicolaou test screening interval recommendations of US providers. STUDY
DESIGN: Using a multistage probability design, we analyzed nationally representative data that were collected in 2006 through the Centers for Disease Control and Prevention's National Ambulatory Medical Care Survey and National Hospital Ambulatory Medical Care Survey.
RESULTS: Approximately 51% of providers ordered the HPV co-test; however, clinical vignettes found that <15% of providers who ordered the HPV test recommend the next Papanicolaou test in 3 years for women with concurrent normal HPV co-test results and a documented normal screening history.
CONCLUSION: Overall, annual cervical cancer screening continues to be a common recommendation, regardless of whether a screening history has been established or an HPV test has been ordered. Published by Mosby, Inc.

Entities:  

Mesh:

Year:  2011        PMID: 21840492     DOI: 10.1016/j.ajog.2011.06.001

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  27 in total

1.  Overview of the CDC Cervical Cancer (Cx3) Study: an educational intervention of HPV testing for cervical cancer screening.

Authors:  Vicki B Benard; Mona Saraiya; April Greek; Nikki A Hawkins; Katherine B Roland; Diane Manninen; Donatus U Ekwueme; Jacqueline W Miller; Elizabeth R Unger
Journal:  J Womens Health (Larchmt)       Date:  2013-12-31       Impact factor: 2.681

2.  Patient knowledge and beliefs as barriers to extending cervical cancer screening intervals in Federally Qualified Health Centers.

Authors:  Nikki A Hawkins; Vicki B Benard; April Greek; Katherine B Roland; Diane Manninen; Mona Saraiya
Journal:  Prev Med       Date:  2013-09-05       Impact factor: 4.018

3.  Cervical cancer screening in the United States and the Netherlands: a tale of two countries.

Authors:  Dik Habbema; Inge M C M De Kok; Martin L Brown
Journal:  Milbank Q       Date:  2012-03       Impact factor: 4.911

Review 4.  Evolution of cervical cancer screening and prevention in United States and Canada: implications for public health practitioners and clinicians.

Authors:  M Saraiya; M Steben; M Watson; L Markowitz
Journal:  Prev Med       Date:  2013-02-08       Impact factor: 4.018

5.  Uptake of HPV testing and extended cervical cancer screening intervals following cytology alone and Pap/HPV cotesting in women aged 30-65 years.

Authors:  Michelle I Silver; Anne F Rositch; Darcy F Phelan-Emrick; Patti E Gravitt
Journal:  Cancer Causes Control       Date:  2017-11-09       Impact factor: 2.506

6.  Acceptable and Preferred Cervical Cancer Screening Intervals Among U.S. Women.

Authors:  Crystale Purvis Cooper; Mona Saraiya; George F Sawaya
Journal:  Am J Prev Med       Date:  2015-07-02       Impact factor: 5.043

7.  Type-specific HPV and Pap test results among low-income, underserved women: providing insights into management strategies.

Authors:  Mona Saraiya; Vicki B Benard; April A Greek; Martin Steinau; Sonya Patel; L Stewart Massad; George F Sawaya; Elizabeth R Unger
Journal:  Am J Obstet Gynecol       Date:  2014-05-06       Impact factor: 8.661

8.  Are uninsured women in a national screening program having longer intervals between cervical cancer screening tests?

Authors:  Shelton J Bartley; Vicki Benard; Eric Tai; Tanner Rockwell; Kristy Kenney; Lisa C Richardson
Journal:  Prev Med       Date:  2020-04-01       Impact factor: 4.018

9.  Optimal interval for routine cytologic screening in the United States.

Authors:  Jane J Kim; Monisha Sharma; Jesse Ortendahl
Journal:  JAMA Intern Med       Date:  2013-02-11       Impact factor: 21.873

10.  Cervical cancer screening among young adult women in the United States.

Authors:  Katherine B Roland; Vicki B Benard; Ashwini Soman; Nancy Breen; Deanna Kepka; Mona Saraiya
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-01-25       Impact factor: 4.254

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.